Imatinib mesylate treatment in a patient with chemoresistant Ph+ acute myeloid leukemia: Possible role of wilms' tumor gene 1 [2]

Tumori

Volumn 93, Issue 2, 2007, Pages 230-231

  Quartarone, Eugenia ^a   Allegra, Alessandro ^a   Alonci, Andrea ^a   Toscano, Giuseppe ^a   Bellomo, Giacomo ^a   Corigliano, Elisabetta ^a   Del Fabro, Vittorio ^a   Musolino, Caterina ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MITOXANTRONE; SOMATOMEDIN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; GENE EXPRESSION; GENE MUTATION; HEMATOPOIESIS; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUTROPENIA; ONCOGENE; PATHOGENESIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WILM TUMOR GENE 1;

EID: 34249878499     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300226     Document Type: Letter

References (10)

1. Jentsch-Ulrich K, Pelz AF, Braun H, Koenigsmann M, Mohren M, Wieacker P, Franke A: Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica, 89: 15, 2004.
2. Viniou NA, Vassilakopoulos TP, Giakoumi X, Mantzouranis M, Pamgalis GA: Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant PH1(+) acute myeloid leukaemia. Eur J Haematol, 72: 58-60, 2004.
3. Ito K, Tominaga K, Suzuki T, Jimai I, Bessho M: Successful treatment with imatinib mesylate in a case of minor bcr/abl-positive acute myelogenous leukaemia. Int J Hematol, 81: 242-245, 2005.
4. Kusumoto S, Murohashi I, Bessho M, Matsumoto H, Shimazu M: The importance of WT1 gene expression in the detection of minimal residual disease. A comparison of WT1 AML/MTG8 transcripts. Rinsho Ketsueki, 40: 511-514, 1999.
5. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia, 19: 1416-1423, 2005.
6. Hu S, Chen Z, Gu W, Chen J, Zhao Y: High expression of RbAp46 gene in patients with acute leukemia or chronic myelogenous leukemia in blast crisis. Chin Med J, 118: 1295-1298, 2005.
7. Englert C, Maheswaran S, Garvin AJ, Kredberg J, Heber DA: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res, 57: 1429-1434, 1997.
8. Ellisen LW, Carless N, Cheng T, Scadden DT, Heber DA: The Wilms' tumor suppressor WT1 directs stage specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J, 20: 1897-1909, 2001.
9. Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U: DANN-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res, 308: 211-221, 2005.
10. Cilloni D, Messa F, Gottardi E, Fava M, Arroga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after short in vitro incubation. Cancer, 101: 979-988, 2004.